M2 Presswire - FDA Issues Early Communication about an Ongoing Review of Vytorin.
On the eve of a date with congressional investigators, executives from Merck and Schering-Plough acknowledged Monday that their blockbuster cholesterol drug, Vytorin, offered no benefit over Zocor.
The news that Vytorin fell short of an old stand-by statin drug, now sold as a cheap generic, sent worried patients scurrying to call their doctors for reassurance and advice.
The irony is that many of those patients are enrolled in a high-stakes clinical trial that might show, once and for all, whether Vytorin and its sister compound Zetia are worth the $5 billion each year that people worldwide are spending on them. If patients in the study decide to bail out, the answer may never be known.
Related Results
Creative Come-Ons Encourage More Generic Utilization
Statins decrease risk of colon cancer: study
Feds close online pharmacy, issue alert
Applications for generics set to surge.(branded pharmaceuticals due to lose p…
Merck and Schering-Plough's statin combo hits pharmacies
“We already have people calling clinical investigators and asking if they should stay in the clinical trial,” says Robert Harrington, director of the Duke Clinical Research Institute. “If you’re a patient taking …
Read the full article with a Free Trial at MyWire.
